Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Return on Sales (2018 - 2026)

Exagen filings provide 9 years of Return on Sales readings, the most recent being 0.0% for Q1 2026.

  • On a quarterly basis, Return on Sales changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.0% in Q1 2026 for Exagen, up from 0.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.0% in Q2 2024 to a low of 0.02% in Q2 2022.
  • Median Return on Sales over the past 5 years was 0.0% (2024), compared with a mean of 0.01%.
  • Biggest five-year swings in Return on Sales: decreased -1bps in 2022 and later rose 2bps in 2023.
  • Exagen's Return on Sales stood at 0.01% in 2022, then surged by 66bps to 0.0% in 2023, then soared by 32bps to 0.0% in 2024, then fell by -2bps to 0.0% in 2025, then increased by 18bps to 0.0% in 2026.
  • The last three reported values for Return on Sales were 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025) per Business Quant data.